Alpheus Medical raises $52M for ultrasound-activated tumor therapy
Summary
Alpheus Medical announced today that it closed an oversubscribed Series B financing round, bringing in $52 million.The Chanhassen, Minnesotabased solid body cancer treatment developer plans to use funds to support a phase 2B randomized controlled trial. The study evaluates the efficacy of its sonodynamic therapy (SDT) for treating newly diagnosed glioblastoma.HealthQuest Capital and Samsara BioCapital co-led the round. Venture investors with interests in cancer care, including BrightEdge, the Brain Tumor Investment Fund and Sontag Innovation Fund, took part too.The complex and diffuse nature of glioblastomas has long hindered therapeutic innovation, said Dr. Conrad Wang Partner at HealthQuest Capital. This investment reflects our commitment to advancing transformative technologies that seek to fill critical gaps in patient unmet needs.Alpheus designed its platform to deliver non-thermal, tumor-selective therapy activated by low-intensity diffuse ultrasound (LIDU) with oral 5-aminolevulinic acid (5-ALA).The technology combination eliminates the need for imaging or sedation. With this support, we are poised to generate pivotal evidence that could help establish a new standard of care for newly diagnosed brain tumors.